Drug
Irinotecan
Irinotecan: highest development phase Approved, developed by Teva, Y-mAbs Therapeutics. 3 trial records tracked on RxWires.
- Highest phase
- Approved
- Developer
- Teva, Y-mAbs Therapeutics
Trials
| Drug | Phase | Indication |
|---|---|---|
| IRINOTECAN HYDROCHLORIDE | Approved | |
| Irinotecan NCT04743661 | Phase 2 | Recurrent Medulloblastoma |
| Irinotecan NCT03189706 | Phase 1 | Neuroblastoma (NB) |
Latest
No recent events.
Follow Irinotecan on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.